Heart Failure With Preserved Ejection Fraction Clinical Trial
— RESPOND-HFOfficial title:
Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF
Verified date | April 2018 |
Source | Medtronic Cardiac Rhythm and Heart Failure |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RESPOND-HF is a prospective, multi-center, non-significant risk pilot study with cross-over design. The purpose of the study is to investigate if rate adaptive pacing has the potential to provide benefit to HF patients with preserved ejection fraction, referred to as HFpEF patients. Findings from this pilot study may be used to guide subsequent efforts to design and conduct a prospective, randomized, multi-center pivotal trial powered to show improvement in patient outcomes.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 31, 2018 |
Est. primary completion date | April 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Age = 18 years or legal age to provide informed consent - Willing and be able to provide informed consent - Previous clinical diagnosis of HF and exhibits HF signs and symptoms consistent with NYHA II or III (or class B or C) - Chronic Rx for heart failure with loop diuretic or a mineralocorticoid receptor antagonist (MRA) - LVEF = 45% within previous 12 months. Acceptable methods include echo, ventriculogram (angiography or nuclear), nuclear stress test. If patient has a prior history of significant left ventricular systolic dysfunction defined as EF < 0.40, patient must have a HF event within previous 12 months defined as: - Hospitalization for decompensated HF - Unscheduled treatment for HF with intravenous loop diuretic or hemofiltration - On stable HF medical therapy for previous 30 days. Dose changes of ACEI / ARB and beta blockers of less than 50% increase or decrease are acceptable for stability - Treadmill exercise time using modified Naughton protocol of greater than 3 min and less than 15 min for men and 14 for women - Medtronic dual chamber pacemaker implanted for = 30 days - Sinus rhythm at rest Exclusion Criteria: - Women who are pregnant or plan to become pregnant - Life expectancy less than 1 year - Enrollment in any concurrent study that could potentially be confounding - Orthopedic, neuromuscular or any other condition limiting exercise testing - Unstable angina or MI or have undergone CABG/PTCA within previous 60 days - A candidate for CABG/PTCA at the time of informed consent - Use of inotrope therapy on a regular basis (e.g. daily, weekly etc.) - Severe and/or poorly controlled major active comorbidity, including (but not limited to): - Diabetes: Hb1AC > 9.5 - Severe COPD: e.g. end stage emphysema managed using 2 or more inhalers and/or using home oxygen - Severe pulmonary disease limiting functional capacity - Hypertension: SBP > 160 mmHg at time of screening - Cancer: Ongoing therapy or therapy within previous 3 months - Severe valvular disease - Renal impairment with serum creatinine > 3 mg/dL - Anemia with hemoglobin < 8 g/dL or major bleeding event within the past 60 days - Primary diagnosis of pulmonary arterial hypertension with ongoing severe pulmonary hypertension and treatment - Known familial hypertrophic cardiomyopathy or hypertrophic obstructive cardiomyopathy - Known restrictive cardiomyopathy or systemic illness known to be associated with infiltrative myocardial disease (e.g. amyloidosis, sarcoidosis, hemochromatosis) - Pericardial restriction or hemodynamically significant pericardial effusion - Patients expected to undergo device or lead replacement within study follow-up duration - Allergies to hydrogel in SEEQ/AVIVO patch - Patients who are expected to be ventricular paced over 40% of the time - Long standing persistent AF Or Ongoing episode of persistent AF |
Country | Name | City | State |
---|---|---|---|
United States | Lindner Research Center | Cincinnati | Ohio |
United States | Ohio State University | Columbus | Ohio |
United States | Mid America Heart Institute (MAHI) | Kansas City | Missouri |
United States | Lancaster General Hospital | Lancaster | Pennsylvania |
United States | Mayo Clinic (Rochester MN) | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Medtronic Cardiac Rhythm and Heart Failure |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exercise time | Exercise time on a treadmill guided by respiratory exchange ratio (RER) during cardiopulmonary exercise test (CPET). | 18 Weeks | |
Secondary | Peak VO2 | Maximum rate of oxygen consumption during treadmill testing | 18 Weeks | |
Secondary | Peak metabolic equivalents (METs) | Ratio of the rate of energy expended during treadmill testing to the rate of energy expended at rest | 18 Weeks | |
Secondary | Peak respiratory exchange ratio (RER) | Maximum ratio between the amount of carbon dioxide (CO2) produced and oxygen (O2) used during treadmill testing | 18 Weeks | |
Secondary | VE/VO2 slope | Minute ventilation oxygen consumption relationship | 18 Weeks | |
Secondary | VO2 at Ventilator Anaerobic Threshold (VAT) | Rate of oxygen consumption at VAT during treadmill testing | 18 Weeks | |
Secondary | VCO2 at Ventilator Anaerobic Threshold (VAT) | Rate of carbon dioxide production at VAT during treadmill testing | 18 Weeks | |
Secondary | KCCQ | Subject's quality of life measure using KCCQ | 18 Weeks | |
Secondary | 6 Minute Hall Walk | Subject's activity of daily living as measure by 6 minute hall walk | 18 Weeks | |
Secondary | Daily Activity | Activity data collected by the implantable device and wearable sensor (SEEQ/AVIVO patch) | 18 Weeks | |
Secondary | Global Patient Health Assessment | Global patient health status using 0-100 visual analog scale | 18 Weeks | |
Secondary | NT-proBNP | N-terminus pro Brain Natriuretic Peptide | 18 Weeks | |
Secondary | Correlation between activity and HR | Correlation between activity and heart rate | 18 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
Recruiting |
NCT03550235 -
Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
|
||
Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
Recruiting |
NCT05582044 -
Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction
|
N/A |